Latham & Watkins Advises Opiant Pharmaceuticals in Sale to Indivior PLC

Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) has announced that it has entered into a definitive merger agreement to be acquired by Indivior Inc, a subsidiary of Indivior PLC (LON: INDV). Under the terms of the agreement, Indivior will acquire all of the outstanding shares of Opiant for upfront consideration of US$20 per share in cash at closing, plus contingent value rights representing, if achieved, potential additional payments over a period of seven years of up to US$8 per share.

Latham & Watkins LLP represents Opiant in the transaction with a corporate deal team led by Chicago partners Christopher Drewry and Max Schleusener, with associates Aidan Milstead, Joshua Reisman, Byron Patton, Jesse Lake, Cyerra McGowan, and Alex Storozum. Advice was also provided on FDA regulatory matters by Washington D.C. partner John Manthei and Bay Area counsel Betty Pang, with associates Nathan Beaton and Meryl Bartlett; on intellectual property matters by Bay Area partner Gabriel Gross, San Diego partner Steven Chinowsky, and San Diego counsel Darryl Steensma, with associates Kathryn Parsons-Reponte and Kristina Funahashi; on benefits and compensation matters by Los Angeles partner Michelle Carpenter and Washington D.C. counsel Laura Szarmach, with associate Joe Benedetto; on finance matters by New York partner Scott Ollivierre, with associate Ricky Burks; on capital markets and securities matters by Chicago partner Scott Westhoff; on litigation matters by Los Angeles partner David Schindler and San Diego partner Colleen Smith; on tax matters by Los Angeles partner Pardis Zomorodi; on real estate matters by Chicago counsel Jeffrey Anderson; on data privacy matters by Bay Area partner Heather Deixler; on CFIUS matters by Washington D.C. partner Jim Barker; and on antitrust matters by Bay Area partner Joshua Holian, with associate Matthew Piehl.